Hepatitis D Virus
Hepatitis D Virus Market

Hepatitis D Virus (HDV) is a viral infection that causes liver inflammation, sometimes leading to severe liver damage. It is caused by the HDV and is considered the most severe form of viral hepatitis in humans due to more rapid progression toward liver-related death and hepatocellular carcinoma. HDV requires hepatitis B virus (HBV) for its replication. HDV infection occurs as co-infection or as super-infection with HBV. 


Simultaneous infection with HBV and HDV can lead to a mild-to-severe or even fulminant hepatitis, whereas the super-infection of HDV on chronic hepatitis B accelerates progression to more severe disease in all ages and 70‒90% of people. 


Hepatitis D Virus Epidemiological Segmentation 

The Epidemiological Segmentation of Hepatitis D Virus in 7MM from 2017 to 2030 is segmented as:- 

  • Total diagnosed prevalent cases of Hepatitis D Virus
  • Gender-specific diagnosed prevalent cases of Hepatitis D Virus
  • Age-specific prevalent cases of Hepatitis D Virus
  • Diagnosed prevalent cases of Hepatitis D Virus by the impact on liver
  • Total treated cases of Hepatitis D Virus 


Hepatitis D Virus Epidemiology 

  • The total diagnosed prevalent cases of Hepatitis D Virus in 7MM were 204,976 in 2017.
  • The prevalent cases of Hepatitis D Virus in the US were 112,673 cases in 2017.


Hepatitis D Virus Market

The therapeutic market of Hepatitis D Virus in 7MM in 2017 was USD 285.1 million. 


Hepatitis D Virus Market Drivers

  • New approval of a drug
  • Novel therapies in pipelines 
  • Increased scientific research and interest


Hepatitis D Virus Market Barriers

  • Lack of standardization in HDV testing
  • Lack of awareness
  • Impact of HBV/HDV in progression to cirrhosis 


Hepatitis D Virus Emerging Drugs 

The Emerging Drugs of the Hepatitis D Virus market are 

And many others. 

  • Hepcludex (Bulevirtide)
  • Lonafarnib
  • Peginterferon Lambda
  • JNJ-73763989 (JNJ-3989)

And many others. 


Hepatitis D Virus Key Players

The key players in the Hepatitis D Virus market are

  • MYR Pharmaceuticals/Hepatera
  • Eiger Biopharmaceuticals
  • Janssen Pharmaceuticals

And many others.